NASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Price, News & Analysis $35.28 -0.14 (-0.40%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$35.28 -0.01 (-0.01%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Celldex Therapeutics Stock (NASDAQ:CLDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Celldex Therapeutics alerts:Sign Up Key Stats Today's Range$34.74▼$35.7650-Day Range$28.56▼$39.9352-Week Range$19.72▼$40.30Volume639,219 shsAverage Volume1.21 million shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/APrice Target$52.77Consensus RatingModerate Buy Company Overview Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity. Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers. Other investigational compounds include varlilumab, an agonist antibody targeting CD27, CDX-301, a recombinant human Flt3 ligand designed to expand dendritic and immune cell populations, and CDX-1140, an antibody targeting CD40 to activate antigen-presenting cells. These programs are in various stages of clinical development, and Celldex collaborates with academic centers and industry partners to advance trials in the United States and select international sites. Founded in 1997 and headquartered in Hampton, New Jersey, Celldex has evolved from a small discovery lab into a specialized immunotherapy company. Under the leadership of President and Chief Executive Officer Roger F. Dansey, M.D., the organization has strengthened its scientific expertise and manufacturing capabilities to support both early-stage and later-stage development activities. Celldex serves patients primarily in North America while maintaining strategic relationships to facilitate broader access to its investigational therapies in other regions.AI Generated. May Contain Errors. Read More Celldex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCLDX MarketRank™: Celldex Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 603rd out of 837 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCelldex Therapeutics has a consensus price target of $52.77, representing about 49.6% upside from its current price of $35.28.Amount of Analyst CoverageCelldex Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celldex Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($4.36) to ($4.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -8.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -8.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celldex Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.30% of the float of Celldex Therapeutics has been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 9.14.Change versus previous monthShort interest in Celldex Therapeutics has recently decreased by 0.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.14 News SentimentCelldex Therapeutics has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Celldex Therapeutics this week, compared to 4 articles on an average week.Search Interest3 people have searched for CLDX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.20% of the stock of Celldex Therapeutics is held by insiders.Percentage Held by InstitutionsCelldex Therapeutics has minimal institutional ownership at this time.Read more about Celldex Therapeutics' insider trading history. Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLDX Stock News HeadlinesMorgan Stanley Lowers Celldex Therapeutics (NASDAQ:CLDX) Price Target to $40.00July 24 at 2:58 AM | americanbankingnews.comWells Fargo & Company Lowers Celldex Therapeutics (NASDAQ:CLDX) Price Target to $48.00July 24 at 2:58 AM | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Canaccord Genuity Group Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock PriceJuly 24 at 1:36 AM | americanbankingnews.comCelldex Therapeutics, Inc.: Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo NodularisJuly 22 at 4:27 PM | finanznachrichten.deCelldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation - SlideshowJuly 22 at 1:11 PM | seekingalpha.comCelldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation TranscriptJuly 22 at 1:10 PM | seekingalpha.comGuggenheim Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $100.00July 22 at 1:36 AM | americanbankingnews.comSee More Headlines CLDX Stock Analysis - Frequently Asked Questions How have CLDX shares performed this year? Celldex Therapeutics' stock was trading at $27.16 on January 1st, 2026. Since then, CLDX stock has increased by 29.9% and is now trading at $35.28. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by $0.03. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.80 million. When did Celldex Therapeutics' stock split? Celldex Therapeutics's stock reverse split on the morning of Monday, February 11th 2019.The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Celldex Therapeutics' major shareholders? Top institutional investors of Celldex Therapeutics include Assenagon Asset Management S.A. (1.00%), Mirador Capital Partners LP (0.23%), Hennion & Walsh Asset Management Inc. (0.06%) and Handelsbanken Fonder AB (0.03%). Insiders that own company stock include Anthony S Marucci, Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi and Diane C Young. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings5/07/2026Today7/24/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CLDX's financial health is in the Green zone, according to TradeSmith. CLDX has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:CLDX CIK744218 Webwww.celldex.com Phone(908) 454-7120Fax908-454-1911Employees150Year Founded1983Price Target and Rating Average Price Target for Celldex Therapeutics$52.77 High Price Target$100.00 Low Price Target$34.00 Potential Upside/Downside+49.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($4.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$258.76 million Net MarginsN/A Pretax Margin-32,753.58% Return on Equity-50.72% Return on Assets-46.59% Debt Debt-to-Equity RatioN/A Current Ratio8.92 Quick Ratio8.92 Sales & Book Value Annual Sales$1.54 million Price / Sales1,798.13 Cash FlowN/A Price / Cash FlowN/A Book Value$7.93 per share Price / Book4.45Miscellaneous Outstanding Shares78,490,000Free Float74,410,000Market Cap$2.77 billion OptionableOptionable Beta0.90 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CLDX) was last updated on 7/25/2026 by MarketBeat.com Staff. From Our PartnersReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
